Podium to Practice: ASH® 2025 – LYMPHOMA: 5 years of follow-up from the Phase 1/2 BRUIN study

Podium to Practice: ASH® 2025 – LYMPHOMA: 5 years of follow-up from the Phase 1/2 BRUIN study

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Carolyn Owen

Icon Chair Speaker

Speakers

Dr. Anca Prica

Dr. Kerry Savage

Studies / Trials Discussed

ID 223 – Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström’s Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström’s Macroglobulinemia (ECWM)

This program has been made possible through unrestricted support from Eli Lilly and Merck.

Studies/trials discussed:

ID 223 – Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström’s Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström’s Macroglobulinemia (ECWM)
Tagged